Stock 6185 CANSINO BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CanSino Biologics Inc.

Equities

6185

CNE100003F01

Delayed Hong Kong S.E.
Other stock markets
 10:14:03 2024-04-25 pm EDT 		5-day change 1st Jan Change
18.34 HKD -0.11% Intraday chart for CanSino Biologics Inc. +11.15% -22.12%
Apr. 22 Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine MT
Apr. 22 Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results MT

Evolution of the average Target Price on CanSino Biologics Inc.

Price target over the last 5 years

History of analyst recommendation changes

914bccb.RsJs5fqtmgoqMyYZH1TNIgFGhkiBJeM58ZTwbWob6ko.J6U5n8rGollbVGsuXRm0T2gI4Bu0HZBLgMzFKgl-iSlwr1ygidrTOlJ9TQ~5d33919fa247513b39cc9e3944b2ed4d

Analyst Recommendations on CanSino Biologics Inc.

Shares in Chinese Pharma Companies Decline Amid Drop in Vaccination Rates MT
Hong Kong Stocks Fall after Fed's Fourth Jumbo Rate Hike; Cansino Slumps 35% MT
UBS Adjusts CanSino Biologics' Price Target to HK$88 From HK$200, Keeps at Buy MT
UBS Adjusts CanSino Biologics’ Price Target to HK$200 From HK$202, Keeps at Buy MT
China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up RE
Market Chatter: CanSino's COVID-19 Vaccine Achieves 65.7% Efficacy Rate for Symptomatic Cases MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.99 CNY
Average target price
24.32 CNY
Spread / Average Target
+43.16%
High Price Target
38.36 CNY
Spread / Highest target
+125.77%
Low Price Target
17.09 CNY
Spread / Lowest Target
+0.60%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CanSino Biologics Inc.

UBS

Ratings for CanSino Biologics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 6185 Stock
  4. Consensus CanSino Biologics Inc.